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Introduction
Neuroprotection refers to strategies that prevent, antagonise, 
interrupt or slow the biochemical and molecular events which 
have the potential to cause the injury and death of brain cells. 
Brain injury is an important adverse complication of 
anaesthesia and surgery, with variable clinical manifestation 
from postoperative cognitive decline, transient ischaemic 
attacks to cerebrovascular accidents (CVAs). Incidences vary 
according to the type of surgery, with up to 80% being reported 
in cardiac surgery.1 Although the injury mechanisms differ 
between neurosurgical and non-neurosurgical procedures, 
the common denominator is failure of glucose and oxygen 
supply, which triggers the cascades of inflammation, oxidative 
stress, mitochondrial dysfunction and excitotoxicity that lead to 
neuronal death by apoptosis and necrosis. 
In the past 40 years, our understanding of the pathophysiology of 
brain injury has grown. Numerous trials have been conducted on 
pharmacological and physiological brain protection strategies. 
Some have been useful in animal (mostly rodent) and preclinical 
studies, but have failed to show benefit in clinical human studies. 
Reasons for this might be discrepancies with regard to the 
experimental duration of ischaemia compared to that in human 
studies,2 a limited understanding of apoptosis, its triggers 
and antagonists, and other undefined pathophysiological 
mechanisms that might not be addressed by a single strategy. 
Importantly, the impact of any neurological deficit in humans 
is likely to be significant in terms of quality of life for which 
cognitive, gross motor and fine motor capabilities are required. 
Hence, relatively acceptable outcomes in animals might not be 
adequate in humans.
This review will differentiate between the interventions by 
comparing acceptable evidence from human trials (“fact”) and 
those without (“fantasy”). 
Fact
The maintenance of arterial blood pressure to within 30% 
of preoperative values is beneficial in the prevention of 
perioperative CVAs in non-cardiac and non-neurosurgical 
procedures, as is the maintenance of blood pressure in the 
immediate postoperative period. Two important studies support 
this; the 2008 Perioperative Ischemic Evaluation (POISE) trial, 
where the use of metoprolol was associated with hypotension, 
death and strokes,3 and a retrospective study carried out by 
Bijker et al, of 48 241 patients who underwent non-cardiac non-
neurosurgical procedures, where hypotension was associated 
with CVAs.4 Although the overall incidence of perioperative CVAs 
is low at 0.05-7.4%,5 and the evidence linking perioperative CVAs 
to hypotension is not based on good-quality randomised trials, 
the expert opinion of members of the Society for Neuroscience 
in Anaesthesiology and Critical Care is that hypotension should 
be prevented. This includes avoiding the initiation of beta 
blockers immediately preoperatively, or carefully titrating new 
beta blockers. 
Equally, numerous retrospective studies on neurosurgical 
procedures have demonstrated the association of intraopeartive 
hypotension with poor neurological outcomes, suggesting that 
cerebral perfusion pressure near 70 mmHg is safer.6-8  
Furthermore, induced hypertension that targets blood pressure 
increases of 20-40% on pre-existing values improves neurological 
outcomes in cerebral aneurysms during endovascular coiling, 
clipping and vasospasm, and in carotid endarterectomies.9 The 
benefit is also found in patients with intracranial pathology that 
has resulted in intracranial hypertension, who have concomitant 
systemic hypertension, and a shift in the autoregulatory 
relationship.
Normoglycaemia, with blood sugar targets of 7.8-10.0 mmol/l 
for neurosurgical and cardiac procedures, is safer than tight 
control, although hyperglycaemia has been associated with 
brain injury when the brain is vulnerable to ischaemia. This is 
supported by the results of the Normoglycaemia in Intensive 
Care Evaluation Survival Using Glucose Algorithm Regulation 
(NICE-SUGAR) study on surgical and non-surgical intensive care 
unit patients, which showed intensive insulin therapy, with 
targets of 4.5-6 mmol/l, to be associated with hypoglycaemia, 
strokes and death.10 Intensive insulin therapy was demonstrated 
to impair glucose utilisation and cause brain energy failure in the 
neurocritical care population.11
As brain ischaemia is caused by the failure of oxygen delivery, 
anaemia is a focus of research in neuroprotection. There is 
evidence of improved outcomes in patients with subarachnoid 
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haemorrhage and a higher haemoglobin.12,13 Since haematocrit 
has the opposite effect on cerebral blood flow and oxygen 
delivery, the optimal haematocrit level which balances the two 
needs to be achieved. Lee et al showed the optimal haematocrit 
for maximum oxygen delivery and maintenance of cerebral 
blood flow to ischaemic brain tissue to be around 30% in a canine 
model of focal brain ischaemia.14 More recently, a haematocrit 
of less than 33% was shown to be a cause of morbidity and 
mortality in elective cranial neurosurgery in a wide variety of 
indications; a threefold higher postoperative mortality risk than 
that for non-anaemic patients.15
Fantasy
Induced hypothermia during neurological surgery as a 
neuroprotective strategy has had disappointing results. A 
Cochrane meta-analysis of four randomised controlled trials on 
mild hypothermia used during neurosurgical procedures failed 
to show benefit in terms of mortality and disability, although the 
hypothermia had no adverse effects.16 The subjects were a mix of 
patients undergoing cerebral aneurysm clipping, craniotomies 
for traumatic brain injury and hemicraniotomies for malignant 
supratentorial infarction. Mild hypothermia may be used because 
it is relatively safe. Hyperthermia should be avoided. Outside 
theatre, it is an established evidence-based neuroprotective 
strategy for comatose patients post out-of-hospital cardiac arrest 
and in neonatal peripartum hypoxic ischaemic encephalopathy.
Volatile anaesthetics have been studied for many years. Although 
their neuroprotective effects are based on sound physiological 
principles, the clinical benefit has not been realised. It has been 
proposed that they work through reducing cerebral metabolism 
and intracranial pressure, anti-seizure activity, the inhibition of 
glutamate release, the activation of gamma-aminobutyric acid 
and glycine receptors, and by minimising intracellular calcium 
and free radical accumulation. Isoflurane delayed, but did 
not prevent, infarction, after a period of ischaemia in a mouse 
experiment by Kawaguchi et al, presumably because it failed to 
inhibit post-ischaemic neuronal apoptosis.17 Human clinical trials 
have also not been able to show meaningful positive outcomes 
in both neurosurgery and non-neurosurgical procedures. A 
difference in stroke occurrence at 30 days post surgery was not 
shown in a widely cited, multicentre randomised controlled trial 
in which stroke incidence was compared in patients undergoing 
carotid endarterectomy under general anaesthetic with volatile 
anaesthetic, versus patients undergoing carotid endarterectomy 
under local anesthesia.18 The noble gas, xenon, is still the subject 
of ongoing research. The protective effects of xenon given 15 
minutes after injury in an animal model of traumatic brain injury 
was demonstrated in a recent study by Campos-Pires et al.19 
This study adds to our knowledge on the subject by providing a 
time frame after the insult within which xenon neuroprotection 
can still be applied. Xenon has been safely used in humans, 
although the costs are prohibitive. Human clinical trials on its 
neuroprotective effects will probably follow soon.
Intravenous anaesthetics, propofol and dexmedetomidine, have 
neuroprotective effects in animal models of brain ischaemia. 
Propofol is the subject of ongoing research in which new 
mechanisms of cerebral preservation have been uncovered, 
including changes in neurotransmitter activity, protein 
expression, the inhibition of apoptosis and the upregulation of 
haeme-oxygenase 1 expression that attenuates ischaemic injury 
by immunomodulation.20 Unfortunately, these benefits need to 
be established in human trials.  
Pharmacological experimental interventions that target the 
pathways of neuronal damage have been studied, including 
anti-excitotoxic, anti-inflammatory, antioxidant, and pre- and 
post-ischaemic conditioning, but have not yielded results that 
can be translated to clinical benefit. 
The neuroprotective effect of drugs in non-neurosurgical 
procedures was reported in a recent systematic review of 
randomised trials by Bilotta et al, whereby the majority under-
went cardiac surgery.21 Twenty-five randomised controlled 
trials in which pharmacological perioperative neuroprotection 
was used were included, particularly when neurological and 
cognitive status was evaluated preoperatively. Atorvastatin and 
magnesium sulphate were associated with a reduced incidence 
of new postoperative deficits, although there was no effect on 
postoperative cognitive decline or mortality. Other agents, such 
as lidocaine, thiopental, S(+)-ketamine, propofol, nimodipine 
and erythropoietin, had no effect on new postoperative deficits 
or postoperative cognitive dysfunction. This review, which 
included single-centre, randomised controlled trials, with a 
heterogeneous mix of surgical procedures, provides hope for 
magnesium and atorvastatin, although magnesium studied 
in subarachnoid haemorrhage had conflicting results. In 
conclusion, the neuroprotective effects of pharmacotherapies 
remain controversial. 
At present, the literature on neuroprotection is open to 
misinterpretation. Interventions that appear to be based on 
sound physiological principles, and which are beneficial in animal 
models, have not been translated to clinical benefit in human 
trials. More trials need to be conducted using higher functioning 
primates to accurately quantify the impact of neuroprotective 
strategies. It seems that maintaining homeostasis, with an 
emphasis on normocarbia, normoxia, blood pressure, glycaemic 
control and adequate haemoglobin concentration, is the only 
proven neuroprotective strategy at present.
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